ChAdOx1.85A+MVA85A

Phase of Development

Phase 2a

Vaccine Platform

Viral Vector

Candidate Overview

ChAdOx1.85A is a simian adenoviral vector expressing Antigen 85A. MVA85A is a modified vaccinia virus Ankara expressing Antigen 85A. The target route of administration for ChAdOx1.85A is aerosol, and intramuscular for MVA85A.

Sponsor / Lead Developer: University of Oxford

Clinical Trial Status: No Active Trials

Primary Indication: Prevention of TB disease

Other Indication(s): Prevention of Mtb infection or sustained infection and Prevention of TB recurrence

Target Population(s): Adolescents, Adults, Children, Infants, People cured of active TB, People living with HIV, People with Mtb infection, and People without Mtb infection

Target Route of Administration: Aerosol and Intramuscular

Clinical Trials

COMPLETED TRIALS
Registry NumberNCT03681860
Clinical Trial PhasePhase 2a
Clinical Trial SponsorUniversity of Oxford
Primary endpoint(s) for this clinical trialSafety
Immunogenicity
Target population(s) for clinical trialAdults
Adolescents
_________________________
Registry NumberNCT01829490
Clinical Trial PhasePhase 1
Clinical Trial SponsorUniversity of Oxford
Primary endpoint(s) for this clinical trialSafety
Target population(s) for clinical trialAdults